Jolene H Fisher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1496717/publications.pdf

Version: 2024-02-01

38	746	14	26
papers	citations	h-index	g-index
38	38	38	750
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 459-467.	5.6	25
2	Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest, 2022, 161, 1320-1329.	0.8	25
3	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine, 2022, 191, 106722.	2.9	3
4	Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. European Respiratory Journal, 2022, 60, 2102571.	6.7	57
5	Correlation of respiratory oscillometry with CT image analysis in a prospective cohort of idiopathic pulmonary fibrosis. BMJ Open Respiratory Research, 2022, 9, e001163.	3.0	7
6	Association of BMI with pulmonary function, functional capacity, symptoms, and quality of life in ILD. Respiratory Medicine, 2022, 195, 106792.	2.9	5
7	The Genomic Classifier and Our Quest for Diagnostic Certainty in Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 725-727.	3.2	O
8	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp> . Respirology, 2022, 27, 635-644.	2.3	12
9	Hospitalizations in Sarcoidosis: A Cohort Study of a Universal Healthcare Population. Annals of the American Thoracic Society, 2021, 18, 1786-1794.	3.2	6
10	Care Delivery Models and Interstitial Lung Disease. Clinics in Chest Medicine, 2021, 42, 347-355.	2.1	4
11	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research, 2021, 22, 202.	3.6	5
12	Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease. Lung, 2021, 199, 379-387.	3.3	4
13	Ophthalmologic assessments in patients with newly diagnosed sarcoidosis: An observational study from a universal healthcare system. Respiratory Medicine, 2021, 187, 106575.	2.9	1
14	The Promise (and Pitfalls) of Administrative Data for Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 9-10.	0.8	0
15	Utility of anti-neutrophil cytoplasmic antibody screening in idiopathic interstitial lung disease. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021015.	0.2	0
16	Idiopathic Pulmonary Fibrosis: A Review of Disease, Pharmacological, and Nonpharmacological Strategies With a Focus on Symptoms, Function, and Health-Related Quality of Life. Journal of Pain and Symptom Management, 2020, 59, 1362-1378.	1.2	20
17	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 147-155.	0.5	3
18	Moving From Multidisciplinary Phenotyping to Biological Classification of Fibrotic Interstitial Lung Disease. Chest, 2020, 158, 1814-1815.	0.8	0

#	Article	IF	CITATIONS
19	Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 226-228.	0.5	2
20	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respiratory Research, 2020, 21, 322.	3.6	18
21	Update in Interstitial Lung Disease 2019. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 500-507.	5.6	17
22	Costs of Workplace Productivity Loss in Patients with Connective Tissue Disease–associated Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1077-1084.	3.2	5
23	Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest, 2020, 158, 1069-1078.	0.8	57
24	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest, 2019, 156, 887-895.	0.8	14
25	Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease. Lung, 2019, 197, 277-284.	3.3	17
26	Epidemiology and health outcomes of sarcoidosis in a universal healthcare population: a cohort study. European Respiratory Journal, 2019, 54, 1900444.	6.7	31
27	Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis. BMC Pulmonary Medicine, 2019, 19, 223.	2.0	52
28	YouTube Videos as a Source of Misinformation on Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2019, 16, 572-579.	3.2	82
29	Role of a Regional Multidisciplinary Conference in the Diagnosis of Interstitial Lung Disease. Annals of the American Thoracic Society, 2019, 16, 455-462.	3.2	35
30	Procedure volume and mortality after surgical lung biopsy in interstitial lungÂdisease. European Respiratory Journal, 2019, 53, 1801164.	6.7	54
31	Systematic review of content and quality of idiopathic pulmonary fibrosis review articles. ERJ Open Research, 2018, 4, 00156-2018.	2.6	2
32	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 234-243.	0.5	8
33	Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 257-258.	0.5	0
34	Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment. Respiratory Medicine, 2017, 125, 65-71.	2.9	13
35	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 133-141.	0.5	15
36	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal, 2016, 2016, 1-7.	1.6	45

#	Article	IF	CITATIONS
37	Accuracy and Reliability of Internet Resources for Information on Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 218-225.	5.6	98
38	Clinical relevance of rheumatoid factor and anti itrullinated peptides in fibrotic interstitial lung disease. Respirology, 0, , .	2.3	4